The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria

<p>Abstract</p> <p>Background</p> <p>Mefloquine and artesunate combination therapy is the recommended first-line treatment for uncomplicated malaria throughout much of south-east Asia. Concerns have been raised about the potential central nervous system (CNS) effects of...

Full description

Bibliographic Details
Main Authors: Singhasivanon Pratap, Viladpainguen Jacher, Thwai Kyaw, Hla Eh, Arunjerdja Ratree, Dubowitz Lilly M, Ambler Michael T, Luxemburger Christine, Nosten François, McGready Rose
Format: Article
Language:English
Published: BMC 2009-09-01
Series:Malaria Journal
Online Access:http://www.malariajournal.com/content/8/1/207
_version_ 1828268141292027904
author Singhasivanon Pratap
Viladpainguen Jacher
Thwai Kyaw
Hla Eh
Arunjerdja Ratree
Dubowitz Lilly M
Ambler Michael T
Luxemburger Christine
Nosten François
McGready Rose
author_facet Singhasivanon Pratap
Viladpainguen Jacher
Thwai Kyaw
Hla Eh
Arunjerdja Ratree
Dubowitz Lilly M
Ambler Michael T
Luxemburger Christine
Nosten François
McGready Rose
author_sort Singhasivanon Pratap
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Mefloquine and artesunate combination therapy is the recommended first-line treatment for uncomplicated malaria throughout much of south-east Asia. Concerns have been raised about the potential central nervous system (CNS) effects of both drug components and there are no detailed reports in very young children.</p> <p>Methods</p> <p>Children, aged between three months and five years, with acute uncomplicated <it>Plasmodium falciparum </it>malaria were randomized to either 7 days of artesunate monotherapy or the same schedule of artesunate plus mefloquine on day 7 and 8. Neurological testing targeting coordination and behaviour was carried out at day 0, 7, 9, 10, 14 and 28. Non-febrile healthy control children from the same population were tested on days 0, 7, 14 and 28.</p> <p>Results</p> <p>From December 1994 to July 1997, 91 children with uncomplicated <it>P. falciparum</it>, 45 treated with artesunate monotherapy, 46 treated with mefloquine and artesunate combination therapy and 36 non-febrile controls, underwent neurological testing. Malaria and fever had a significant negative impact on testing performance. By contrast, the anti-malarial treatments were not associated with worsening performances in the various components of the test. Artesunate and mefloquine do not appear to have a significant influence on coordination and behaviour. Children treated with mefloquine were significantly less likely to suffer recurrent malaria infection during follow-up compared to those treated with artesunate alone (P = 0.033).</p> <p>Conclusion</p> <p>In keeping with the results of randomized controlled trials in adults, mefloquine was not associated with a decrease in specific items of neurological performance. Likewise, children treated with artesunate did not perform significantly differently to control children. This study does not exclude subtle or rare treatment CNS effects of artesunate or mefloquine. Treatment of acute uncomplicated malaria results in a significant improvement on items of neurological performance.</p>
first_indexed 2024-04-13T05:13:54Z
format Article
id doaj.art-a26b3243125f452080349d86b8a993d8
institution Directory Open Access Journal
issn 1475-2875
language English
last_indexed 2024-04-13T05:13:54Z
publishDate 2009-09-01
publisher BMC
record_format Article
series Malaria Journal
spelling doaj.art-a26b3243125f452080349d86b8a993d82022-12-22T03:00:57ZengBMCMalaria Journal1475-28752009-09-018120710.1186/1475-2875-8-207The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malariaSinghasivanon PratapViladpainguen JacherThwai KyawHla EhArunjerdja RatreeDubowitz Lilly MAmbler Michael TLuxemburger ChristineNosten FrançoisMcGready Rose<p>Abstract</p> <p>Background</p> <p>Mefloquine and artesunate combination therapy is the recommended first-line treatment for uncomplicated malaria throughout much of south-east Asia. Concerns have been raised about the potential central nervous system (CNS) effects of both drug components and there are no detailed reports in very young children.</p> <p>Methods</p> <p>Children, aged between three months and five years, with acute uncomplicated <it>Plasmodium falciparum </it>malaria were randomized to either 7 days of artesunate monotherapy or the same schedule of artesunate plus mefloquine on day 7 and 8. Neurological testing targeting coordination and behaviour was carried out at day 0, 7, 9, 10, 14 and 28. Non-febrile healthy control children from the same population were tested on days 0, 7, 14 and 28.</p> <p>Results</p> <p>From December 1994 to July 1997, 91 children with uncomplicated <it>P. falciparum</it>, 45 treated with artesunate monotherapy, 46 treated with mefloquine and artesunate combination therapy and 36 non-febrile controls, underwent neurological testing. Malaria and fever had a significant negative impact on testing performance. By contrast, the anti-malarial treatments were not associated with worsening performances in the various components of the test. Artesunate and mefloquine do not appear to have a significant influence on coordination and behaviour. Children treated with mefloquine were significantly less likely to suffer recurrent malaria infection during follow-up compared to those treated with artesunate alone (P = 0.033).</p> <p>Conclusion</p> <p>In keeping with the results of randomized controlled trials in adults, mefloquine was not associated with a decrease in specific items of neurological performance. Likewise, children treated with artesunate did not perform significantly differently to control children. This study does not exclude subtle or rare treatment CNS effects of artesunate or mefloquine. Treatment of acute uncomplicated malaria results in a significant improvement on items of neurological performance.</p>http://www.malariajournal.com/content/8/1/207
spellingShingle Singhasivanon Pratap
Viladpainguen Jacher
Thwai Kyaw
Hla Eh
Arunjerdja Ratree
Dubowitz Lilly M
Ambler Michael T
Luxemburger Christine
Nosten François
McGready Rose
The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
Malaria Journal
title The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
title_full The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
title_fullStr The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
title_full_unstemmed The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
title_short The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated <it>Plasmodium falciparum </it>malaria
title_sort neurological assessment in young children treated with artesunate monotherapy or artesunate mefloquine combination therapy for uncomplicated it plasmodium falciparum it malaria
url http://www.malariajournal.com/content/8/1/207
work_keys_str_mv AT singhasivanonpratap theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT viladpainguenjacher theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT thwaikyaw theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT hlaeh theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT arunjerdjaratree theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT dubowitzlillym theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT amblermichaelt theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT luxemburgerchristine theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT nostenfrancois theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT mcgreadyrose theneurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT singhasivanonpratap neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT viladpainguenjacher neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT thwaikyaw neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT hlaeh neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT arunjerdjaratree neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT dubowitzlillym neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT amblermichaelt neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT luxemburgerchristine neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT nostenfrancois neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria
AT mcgreadyrose neurologicalassessmentinyoungchildrentreatedwithartesunatemonotherapyorartesunatemefloquinecombinationtherapyforuncomplicateditplasmodiumfalciparumitmalaria